Gilead Sciences Completes Acquisition of MiroBio

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of its previously announced transaction to acquire MiroBio, a privately held British biotechnology company focused on immune restoration is concentrating agonists targeting immune-suppressing receptors for approximately $405 million in cash. The acquisition provides Gilead with MiroBio’s proprietary research platform and entire portfolio of immunosuppressive receptor agonists. MiroBio’s lead investigational antibody, MB272, is a selective B and T lymphocyte attenuator (BTLA) immunosuppressive receptor agonist and has entered Phase 1 clinical trials, with the first patient dosed in early August 2022. MB272 targets T, B and dendrite cells to inhibit or attenuate activation and suppress an inflammatory immune response.

“Inflammation is a key area of ​​focus for Gilead, and MiroBio’s novel research platform technology and pipeline offers the opportunity to develop potentially first-in-class large molecule therapeutics to help patients with currently unmet medical needs,” said Flavius ​​Martin, executive vice president, Research, Gilead Sciences. “This novel approach to inflammatory diseases has the potential to be an important part of delivering durable remission to patients living with complex and chronic immune-mediated diseases.”

Also Read :  Bitcoin, Ethereum, Dogecoin Slide: Analyst Says It's Time To Stash Up On Apex Crypto - Bitcoin (BTC/USD), Ethereum (ETH/USD), Dogecoin (DOGE/USD)

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has been pursuing and making breakthroughs in medicine for more than three decades with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, inflammation and cancer. Gilead operates in more than 35 countries worldwide and is headquartered in Foster City, California.

Gilead Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and other factors, including difficulties or unanticipated expenses relating to the integration of the companies, including the impact of the transaction on relationships with employees, other business partners or government agencies; the risk that Gilead may not realize the anticipated benefits of this transaction; Gilead’s ability to advance MiroBio’s product pipeline and successfully commercialize MiroBio’s products; the parties’ ability to initiate and complete clinical trials of such products in the currently anticipated timelines, or at all; the possibility of unfavorable results from one or more of these studies involving such products; Uncertainties related to regulatory submissions and associated filing and approval deadlines, including the risk that the FDA may not approve such products in the anticipated indications or within the deadlines or at all, and any marketing approvals, if granted, may place significant limitations on their use to have ; any assumptions underlying the foregoing; and other risks and uncertainties discussed from time to time in Gilead’s periodic reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including current reports on Form 8-K, quarterly reports on Form 10 -Q and annual reports on Form 10-K. These risks, uncertainties and other factors could cause actual results to differ materially from those projected in the forward-looking statements. All statements, other than statements of historical fact, are statements that may be deemed to be forward-looking statements. Investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intention to update any such forward-looking statements.

Also Read :  CoreStack Accelerates Vision and Growth with Acquisition of Optio3

Gilead and the Gilead logo are trademarks of
Gilead Sciences, Inc. or its affiliates.

For more information about Gilead, visit the company’s website at

follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Also Read :  Elon Musk-Twitter saga: A look at the major players

Jacquie Ross, Investors

[email protected]

Cathy Cantone, Media

(908) 327-3013

Source: Gilead Sciences, Inc.

Source link